Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 9/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15283617 | 0.76 | DRD2 (0.38) | CHRM5CHRM1HTR6MAPT | |
| SCHEMBL17313489 | 0.74 | BRD4 (0.45) | MAPT | |
| SCHEMBL28436551 | 0.74 | CHRM5 (0.36) | CHRM5CHRM1 | |
| SCHEMBL17313491 | 0.73 | TP53 (0.37) | CHRM1HTR6TSPOMAPT | |
| SCHEMBL17580583 | 0.71 | DRD2 (0.40) | HTR6PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17313485 | 0.70 | PKM (0.39) | CHRM1 | |
| SCHEMBL2182332 | 0.64 | MAOA (0.46) | HTR6CHRNA7TSPO | |
| SCHEMBL18309476 | 0.61 | HTR1A (0.48) | HTR6MAPT | |
| SCHEMBL282691 | 0.60 | CHRM1 (0.48) | CHRM5CHRM1 | |
| SCHEMBL9270829 | 0.60 | ALDH1A1 (0.47) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744176-B2 | Therapeutic uses of novel thienopyrimidine derivatives | SANOFI (FR) | 2017-08-29 | — | — | US | disclosed |
| US-20150352124-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352124-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | CHRM5 3785/4885CHRM1 3562/4885HTR6 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.